Impact of food and different meal types on the pharmacokinetics of rilpivirine. - Wikidata - awgldk - TriplyDB

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

http://www.wikidata.org/entity/Q42261088

about

Medication Adherence and Health Outcomes of People Living with HIV Who Are Food Insecure and Prescribed Antiretrovirals That Should Be Taken with Food.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of a Triple-Therapy Regimen in a Critically Ill Patient with HIV.Class-specific relative genetic contribution for key antiretroviral drugs.Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection

P2860

Q30628813-D242FF44-9CB6-4CC8-AD4C-A3935DDF3B3E Q34976284-CA83B815-4717-432D-BDCB-05BA770E2EFF Q37538683-4849DB55-142A-4E1E-89AB-BA6068AF4150 Q38168930-884E8A8E-CDA0-4FDB-BD90-BC01C6DB29C0 Q38750666-1BA14826-B46B-4DAB-964F-375582369FE0 Q38860042-84431A31-7DB1-4742-AC05-28150ECD5A59 Q38960937-C60A67BE-9B7A-498C-8AEA-B0FF1D11AF9B Q38980007-556748BD-0586-449D-BAAD-937AB70D6416 Q41219268-C99589EB-8ACE-42EE-B84F-403C3D288C61 Q41230514-0827B607-0D67-4669-BD18-FD8DF91EB967 Q42199901-17A355C7-0E6D-4F1F-AB33-E31ACE7DBA9B Q42211662-7CE83160-8919-4CD2-A6E5-56D4B9129BDD Q42241537-C8B7342E-FD27-4912-90A6-0BB0DB590891 Q46302088-30620A81-9B71-41B4-BA97-145C31D74FC5 Q47301806-BD3054A5-A6A7-4869-A725-CABA411636FD Q54942910-6CFD0526-8BD7-4CA7-B9F7-8B8C093BA536 Q58700561-9D07DA3C-386C-4827-9C09-54763DF77258

P2860

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

http://www.wikidata.org/entity/Q42261088

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

@en

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

@nl

type

label

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

@en

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

@nl

prefLabel

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

@en

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

@nl

P1433

Q42261088-B9D94D3E-547A-4878-9FA3-3AD3F478D33B

P1476

Q42261088-C798281E-4582-441D-BDD2-3F268C079BFE

P2093

Q42261088-00899C33-A4D3-417D-A01D-7D57F12CEC3A

Q42261088-0C4F5867-2F52-4153-BE5B-92CF7879E66D

Q42261088-55833989-EDDB-4918-BC6B-471826CC6CE0

Q42261088-CB70C0C4-52F8-493A-A3B5-AE254B37A569

Q42261088-D4187899-4849-4913-BA77-7A3EFC08A4A0

Q42261088-EAC4EB5B-5A1B-4A0C-8AC6-BC221B4F9000

P2860

Q42261088-069E7CE9-FFE4-4BD4-9033-08C282DE0BC2

Q42261088-14AD90F3-0AA5-4DF2-BA2E-21CE256210F0

Q42261088-1EA8207F-152E-463C-9885-6FD4C7BF01E4

Q42261088-36277504-2E2B-4A1E-B225-2EEEC491FB15

Q42261088-3E3B22AE-AA5A-4638-B04E-231644494D8C

Q42261088-55431F3F-C4AB-4901-B31E-30A88D7D6A87

Q42261088-6987E722-971F-44C2-BD89-76CE7C2F8C97

Q42261088-82BC2F0C-9FE3-4E6D-BE24-D08737D2D51B

Q42261088-B8C6DF55-865A-4614-93E5-8067246BBCA0

Q42261088-C14CAA1A-8412-4A60-9A44-26902D1FC3C7

P304

Q42261088-D82AA092-2D13-4590-8C90-5B754F986F01

P31

Q42261088-361612CA-65F6-4800-BDB3-C04D9130207F

P356

Q42261088-62E523EB-A08C-440A-9210-59509BA19118

P433

Q42261088-2739F1A4-9B20-4132-B2EB-4087202F764C

P478

Q42261088-9C903513-9F6C-45B5-9483-71890F840931

P577

Q42261088-A84925D4-4B2E-4222-BA22-B046F1106586

P698

Q42261088-96585622-7A4A-418A-B604-972776655FCF

P356

P1433

The Journal of Clinical Pharmacology

P1476

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

@en

P2093

Annemie Buelens

http://www.w3.org/2001/XMLSchema#string

Herta M Crauwels

http://www.w3.org/2001/XMLSchema#string

Katia Boven

http://www.w3.org/2001/XMLSchema#string

Marita Stevens

http://www.w3.org/2001/XMLSchema#string

Richard M W Hoetelmans

http://www.w3.org/2001/XMLSchema#string

Rolf P G van Heeswijk

http://www.w3.org/2001/XMLSchema#string

P2860

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.

Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.

Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Food effects on tablet disintegration.

P304

834-840

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.107

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23720136

http://www.w3.org/2001/XMLSchema#string